SELLAS Life Sciences Group, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
SELLAS Life Sciences Group, Inc. (SLS) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-08-14.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2017-08-14
- SELLAS Life Sciences Group, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-06-30 was 138.27K shares.
- SELLAS Life Sciences Group, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-06-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month |
|---|---|---|---|
| 2017-06-30 | 0.00 shares 10-Q · filed 2017-08-14 | 0.00 shares 10-Q · filed 2017-08-14 | |
| 2016-06-30 | 138.27K shares 10-Q · filed 2017-08-14 | 2.77M shares 10-Q · filed 2016-08-09 | 0.00 shares 10-Q · filed 2017-08-14 |
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-09 | 0.00 shares 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |